BIOFRONTERA AG/ADR (NASDAQ:BFRA) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus target price of $21.75 for the company, according to Zacks. Zacks has also given BIOFRONTERA AG/ADR an industry rank of 74 out of 256 based on the ratings given to its competitors.
Several research analysts have weighed in on BFRA shares. Lake Street Capital upped their price objective on shares of BIOFRONTERA AG/ADR from $19.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Benchmark reiterated a “buy” rating on shares of BIOFRONTERA AG/ADR in a research note on Tuesday, March 26th.
BFRA opened at $17.00 on Thursday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 3.38 and a current ratio of 3.84. The business’s fifty day simple moving average is $15.86. BIOFRONTERA AG/ADR has a 1-year low of $11.04 and a 1-year high of $18.32. The firm has a market capitalization of $363.53 million, a P/E ratio of -36.17 and a beta of 0.89.
BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings data on Wednesday, May 29th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. BIOFRONTERA AG/ADR had a negative net margin of 62.81% and a negative return on equity of 95.81%. The firm had revenue of $7.73 million for the quarter.
About BIOFRONTERA AG/ADR
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.
Further Reading: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.